Hepatology Forum最新文献

{"title":"Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination.","authors":"Ankoor H Patel,&nbsp;Rajan Amin,&nbsp;Alexander T Lalos","doi":"10.14744/hf.2022.2022.0019","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0019","url":null,"abstract":"<p><p>IgG4-related disease (IgG4-RD) is a fibro-inflammatory disease that can affect multiple organs. Autoimmune pancreatitis type 1 is a manifestation of IgG4-RD and can often mimic tumor-like masses. Autoimmune phenomena following COVID-19 mRNA vaccination are being increasingly reported. Currently, there are no cases in which IgG4-RD involving the hepatobiliary system has been reported following the COVID-19 vaccination. We present the first case of IgG4-RD and AIP type 1 to be associated with the mRNA-based COVID-19 vaccination.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"97-99"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/60/hf-3-097.PMC9510734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portal vein thrombosis risk factors in liver transplant candidates.","authors":"Cagatay Ak,&nbsp;Gupse Adali,&nbsp;Suleyman Sayar,&nbsp;Abdulbaki Agackiran,&nbsp;Fatma Kulali,&nbsp;Resul Kahraman,&nbsp;Oguzhan Ozturk,&nbsp;Kamil Ozdil","doi":"10.14744/hf.2022.2022.0005","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0005","url":null,"abstract":"<p><strong>Background and aim: </strong>Portal vein thrombosis (PVT) is particularly detected in advanced liver cirrhosis patients. We aimed to analyze the risk factors for PVT in liver transplant candidates.</p><p><strong>Materials and methods: </strong>Dataset for consecutive 165 cirrhotic patients who were evaluated for liver transplantation (LT) were retrospectively analyzed. We sorted patients into two groups: patients with PVT and patients without PVT. Included variables were age, sex, etiology of liver disease, body mass index, MELD-Na score, Child-Pugh score, clinical variables reflecting portal hypertension, and hepatocellular carcinoma. Univariate and multivariate logistic regression analyses were used to identify risk factors of PVT.</p><p><strong>Results: </strong>Of 165 LT candidates, 46 had PVT (27.9%). Ascites, thrombocytopenia, history of variceal bleeding, and band ligation were risk factors for PVT in univariate analysis. In multivariate analysis, only a history of variceal bleeding (OR 3.45, 95% CI 1.02-11.6, p=0.046) significantly increased the risk of PVT.</p><p><strong>Conclusion: </strong>The previous history of variceal bleeding predicts PVT development in cirrhosis, suggesting that the severity of portal hypertension is a major predictive factor for PVT in patients with cirrhosis. Future prospective studies are needed to risk stratifying cirrhosis patients prior to LT for future PVT development and to define the prophylactic role of anticoagulation in these patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"88-92"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/8a/hf-3-088.PMC9510737.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy.","authors":"Berat Ebik,&nbsp;Mustafa Aygan,&nbsp;Elif Tugba Tuncel,&nbsp;Huseyin Kacmaz,&nbsp;Nazim Ekin,&nbsp;Medeni Arpa,&nbsp;Kendal Yalcin","doi":"10.14744/hf.2022.2022.0016","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0016","url":null,"abstract":"<p><strong>Background and aim: </strong>Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies.</p><p><strong>Materials and methods: </strong>The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected.</p><p><strong>Results: </strong>Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, p=0.003).</p><p><strong>Conclusion: </strong>There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"82-87"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/d2/hf-3-082.PMC9510740.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NSAID-associated drug-induced liver injury prior to and following liver transplantation.","authors":"Mesut Gumussoy,&nbsp;Hale Gokcan,&nbsp;Emin Bodakci,&nbsp;Saba Kiremitci,&nbsp;Berna Savas,&nbsp;Ramazan Idilman","doi":"10.14744/hf.2021.2021.0050","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0050","url":null,"abstract":"Case Report A 43-year-old male patient was admitted to the outpatient clinic for nausea, jaundice, and dark-colored urine in July 2019. He has been taking dexketoprofen/diclofenac sodium twice a week for headaches. He consumed 25 packs of cigarettes per year and 60–70 g of alcohol per week for 2 years. On his physical examination, he was icteric and had mild epigastric tenderness. At that time, his serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 897 U/L (0–50) and 1799 U/L (0–50), respectively. His serum alkaline phosphatase (ALP) level was 141 U/L (40–130), gammaglutamyl transferase (GGT) 158 U/L (10–71), total bilirubin 7.4 mg/dL (0.1–1.2), direct bilirubin 4.3 mg/dL, and albumin 2.7 g/dL (3.5–5.2). INR was 1.32. Serological studies for viral hepatitis, autoimmune panel, and metabolic panel were all normal. We diagnosed NSAID-induced toxic hepatitis. After the drug was discontinued, his laboratory values returned to the normal range. He was discharged with normal liver tests. The patient was admitted to our clinic with jaundice 45 days after he was discharged. He was on intermittent NSAIDs. His serum AST and ALT levels were 1391 U/L and 1680 U/L, respectively. His serum ALP level was 113 U/L, GGT 104 U/L, total bilirubin 18.2 mg/dL, and direct bilirubin 14.2 mg/dL. His INR was 3.1. Medical supportive treatment was initiated. Hepatic encephalopathy was developed on the seventh day of hospitalization, and INR was 5.0. Plasmapheresis was started. His clinical status and encephalopathy worsened. Living donor liver transplantation was performed on the 16th day of admission. Explant liver pathology was revealed with submassive necrosis characterized by severe liver parenchyma loss accompanied by a marked ductular reaction and regenerative nodule (Fig. 1a, b). He was discharged from the hospital in Oct 2019. During the posttransplant follow-up period, liver test abnormality was detected. His serum AST, ALT, ALP, and GGT levels were 407 U/L, 729 U/L, 250 U/L, and GGT 280 U/L, respectively. His total bilirubin level was 2.1 mg/dL. He was on flurbiprofen 2–3 times a month for headaches. Liver biopsy was performed. Liver biopsy revealed mild portal and lobular inflammatory lesion combined with a cholestatic reaction was remarkable biopsy findings were primarily compatible with drug-induced injury (Fig. 2). Methylprednisolone was started with a dose of 1 mg/kg per day. His aminotransferase levels were decreased, but cholestatic parameters were stable. Magnetic resonance cholangiopancreatography revealed biliary stenosis on the anastomotic site. A plastic biliary stent was placed during endoscopic retrograde cholangiopancreatography. The patient is currently very well with normal liver tests. Dear Editor,","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"108-109"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/5d/hf-3-108.PMC9510739.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell-free methylation of RASSF1 and CDKN2AIP genes in the diagnosis of hepatocellular carcinoma associated with hepatitis B virus cirrhosis.","authors":"Pelin Telli,&nbsp;Nazli Begum Ozturk,&nbsp;Mehmet Tolgahan Hakan,&nbsp;Bilger Cavus,&nbsp;Asli Cifcibasi Ormeci,&nbsp;Aysun Yakut,&nbsp;Volkan Senkal,&nbsp;Ziya Imanov,&nbsp;Arzu Poyanli,&nbsp;Emine Goknur Isik,&nbsp;Kadir Demir,&nbsp;Fatih Besisik,&nbsp;Sabahattin Kaymakoglu,&nbsp;Ilhan Yaylim,&nbsp;Filiz Akyuz","doi":"10.14744/hf.2022.2022.0021","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0021","url":null,"abstract":"<p><strong>Background and aim: </strong>Chronic hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC). Circulating cell-free DNA (cfDNA) methylation of tumor suppressor genes are emerging potential biomarkers in HCC. We aimed to evaluate the cfDNA methylation status of RASSF1 and CDKN2AIP genes in patients with liver cirrhosis (LC) with or without HCC caused by HBV.</p><p><strong>Materials and methods: </strong>A total of 47 patients with HBV cirrhosis were included in the study. Patients were divided into two groups: HCC and LC (HCC+LC, n=22) and HBV cirrhosis only (LC, n=25). cfDNA was isolated from the plasma samples of the patients. Methylation analysis was performed for RASSF1 and CDKN2AIP genes.</p><p><strong>Results: </strong>Mean methylation percentage of CDKN2AIP gene was 0.001±0.004% in the HCC+LC group and 0.008±0.004 % in the LC only group. The mean methylation percentage of RASSF1 gene was 5.1±16.1% in the HCC+LC group and 9.7±25.9% in the LC only group. The methylation rate of CDKN2AIP was significantly lower in the HCC+LC group (p=0.027). A positive correlation was found with the absence of cfDNA methylation of CDKN2AIP gene in the presence of HCC (R=0.667, p=0.018).</p><p><strong>Conclusion: </strong>cfDNA methylation of CDKN2AIP and RASSF1 genes may provide important diagnostic information regarding the development of HCC in the setting of HBV cirrhosis.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"77-81"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/f2/hf-3-077.PMC9510732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation in developing countries.","authors":"Nazli Begum Ozturk,&nbsp;Haris Muhammad,&nbsp;Merve Gurakar,&nbsp;Alperen Aslan,&nbsp;Ahmet Gurakar,&nbsp;Doan Dao","doi":"10.14744/hf.2022.2022.0014","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0014","url":null,"abstract":"<p><p>With the increasing incidence and prevalence of end-stage liver disease, demand for donor grafts continues to increase. Approaches on maximizing the potential donor grafts vary depending on the region. This review aims to summarize the current practice of liver transplantation with an emphasis on challenges encountered in developing countries.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"103-107"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/86/hf-3-103.PMC9510741.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of patients with hepatocellular carcinoma: A multicenter study.","authors":"Fatih Guzelbulut,&nbsp;Umit Karaogullarindan,&nbsp;Hikmet Akkiz,&nbsp;Engin Altintas,&nbsp;Coskun Ozer Demirtas,&nbsp;Ozgur Bahadir,&nbsp;Caglayan Keklikkiran,&nbsp;Abdullah Emre Yildirim,&nbsp;Mesut Gumussoy,&nbsp;Hatice Rizaoglu Balci,&nbsp;Pinar Gokcen,&nbsp;Dilara Turan Gokce,&nbsp;Cem Simsek,&nbsp;Ilker Turan,&nbsp;Guray Can,&nbsp;Volkan Gokbulut,&nbsp;Serkan Yaras,&nbsp;Gupse Adali,&nbsp;Remzi Adnan Akdogan,&nbsp;Ufuk Avcioglu,&nbsp;Mehmet Demir,&nbsp;Hamdi Levent Doganay,&nbsp;Sezgin Vatansever,&nbsp;Hale Sumer,&nbsp;Feyza Dilber,&nbsp;Meral Akdogan Kayhan,&nbsp;Hatice Yasemin Balaban,&nbsp;Halis Simsek,&nbsp;Osman Cavit Ozdogan,&nbsp;Ulus Salih Akarca,&nbsp;Zeki Karasu,&nbsp;Fulya Gunsar,&nbsp;Ramazan Idilman","doi":"10.14744/hf.2022.2022.0028","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0028","url":null,"abstract":"<p><strong>Background and aim: </strong>The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients with HCC.</p><p><strong>Materials and methods: </strong>The study comprised 1802 HCC patients diagnosed and followed up by Liver Diseases Outpatient Clinics in 14 tertiary centers in Turkey between 2001 and 2020.</p><p><strong>Results: </strong>The mean age was 62.3±10.7 years, and 78% of them were males. Of the patients, 82% had cirrhosis. Hepatitis B virus (HBV) infection was the most common etiology (54%), followed by hepatitis C virus (HCV) infection (19%) and nonalcoholic fatty liver disease (NAFLD) (10%). Of the patients, 56% had a single lesion. Macrovascular invasion and extrahepatic spread were present in 15% and 12% of the patients, respectively. The median serum alpha-fetoprotein level was 25.4 ng/mL. In total, 39% of the patients fulfilled the Milan Criteria. When we compared the characteristics of patients diagnosed before and after January 2016, the proportion of NAFLD-related HCC cases increased after 2016, from 6.6% to 13.4%.</p><p><strong>Conclusion: </strong>Chronic HBV and HCV infections remain the main causes of HCC in Turkey. The importance of NAFLD as a cause of HCC is increasing.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"71-76"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/74/hf-3-071.PMC9510736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care in cirrhotic patients: Brief summary of recent AASLD guidance.","authors":"Osman Cavit Ozdogan","doi":"10.14744/hf.2022.2022.0023","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0023","url":null,"abstract":"<p><p>Palliative care in decompensated cirrhotic patients is a developing concept which should be used in cirrhotic patients during the advanced and terminal stages. Hepatologists and liver transplant teams mostly ignore the patients palliative care issues while intensively dealing with the liver diseases and its complications. This review is a brief summary of the recently published guidance discussing the palliative care, symptom based treatments and end of life with a collaborative and standartized approach which is recommended to all health care workers of cirrhotic patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"100-102"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/07/hf-3-100.PMC9510738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Report of the ministry of health working group on standardization of living donor liver transplantation in Turkiye.","authors":"Veysel Umman,&nbsp;Murat Zeytunlu,&nbsp;Zeki Karasu,&nbsp;Bulent Aydinli,&nbsp;Fatih Kaciroglu,&nbsp;Yusuf Yavuz,&nbsp;Ahmet Tekin,&nbsp;Sukru Emre","doi":"10.14744/hf.2022.2021.0047","DOIUrl":"https://doi.org/10.14744/hf.2022.2021.0047","url":null,"abstract":"<p><p>Liver transplantation is successfully achieved all over the world and in Turkiye. Similar to many middle and far east countries, donation from deceased donors has not reached the desired level in Turkiye. Therefore, in Turkiye, living donors have been frequently used for liver transplantation. Although Turkiye is the leading country in Europe and one of the top three countries in the world executing LDLT, nationwide standardization of LDLT protocols, including donor and recipient evaluation and acceptance criteria, donor and recipient follow-up and reporting rules, and routine periodic audits by the ministry of health authorities, has not been established. Therefore, we created a working group to study reviewing regulations of LDLT operation in Europe and the USA. The establishment and implementation of standardization of LDLT operation will serve to improve the donor and recipient outcomes while preventing incomplete or incorrect practices. The guide prepared on this subject is presented in the Appendix.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"93-94"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/b0/hf-3-093.PMC9510742.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxic hepatitis case with prolonged jaundice due to Favipiravir.","authors":"Ramazan Yolacan,&nbsp;Umit Karabulut,&nbsp;Ali Uzel,&nbsp;Feyzullah Ucmak,&nbsp;Muhsin Kaya","doi":"10.14744/hf.2022.2022.0007","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0007","url":null,"abstract":"<p><p>Favipiravir (FPV) is an antiviral drug used in the treatment of severe acute respiratory syndrome coronavirus 2 infection. The main side effects of this drug are teratogenicity and hyperuricemia. Limited information is available on other side effects. Here, we aimed to present our toxic hepatitis case with prolonged jaundice after FPV treatment.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 3","pages":"95-96"},"PeriodicalIF":0.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/68/hf-3-095.PMC9510735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}